Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.40 |
| ▸ | AOC2 | O75106 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038148 | 0.81 | CYP19A1 (0.43) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL8038143 | 0.81 | CYP19A1 (0.43) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL8042053 | 0.81 | CYP19A1 (0.43) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL8036024 | 0.81 | CYP19A1 (0.43) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL8042060 | 0.81 | CYP19A1 (0.43) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL21900740 | 0.79 | CYP19A1 (0.42) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL10750638 | 0.78 | CYP19A1 (0.41) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL4068104 | 0.77 | CYP19A1 (0.45) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL19230319 | 0.77 | CYP19A1 (0.45) | CYP19A1AOC2MAOAMAOBDAO | |
| SCHEMBL8038103 | 0.77 | AOC2 (0.43) | CYP19A1AOC2MAOAMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2000076990-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| EP-0283522-B1 | TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4932998-A | LOW PHYTOTOXICITY FOR PADDY RICE PLANTS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0283522-A1 | TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CYP19A1 2436/4885AOC2 2888/4885MAOA 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.